Does the media refer more to SMMT or MRK?

In the previous week, Merck & Co., Inc. had 51 more articles in the media than Summit Therapeutics. MarketBeat recorded 53 mentions for Merck & Co., Inc. and 2 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.37 beat Summit Therapeutics' score of 0.84 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merck & Co., Inc. 46 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger earnings & valuation, SMMT or LPA?

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Logistic Properties of the Americas $50.13M 2.33 $10.50M N/A N/A

Does the media refer more to SMMT or LPA?

In the previous week, Logistic Properties of the Americas had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for Logistic Properties of the Americas and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat Logistic Properties of the Americas' score of 0.29 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Logistic Properties of the Americas 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, RVMD or SMMT?

Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revolution Medicines N/A N/A -$1.13B -$7.07 N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is RVMD or SMMT more profitable?

Revolution Medicines' return on equity of -83.22% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -83.22% -59.06% Summit Therapeutics N/A -291.24% -243.07%

Does the media refer more to RVMD or SMMT?

In the previous week, Revolution Medicines had 20 more articles in the media than Summit Therapeutics. MarketBeat recorded 22 mentions for Revolution Medicines and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat Revolution Medicines' score of 0.29 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMMT or ONC?

In the previous week, BeOne Medicines had 10 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for BeOne Medicines and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat BeOne Medicines' score of -0.18 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Summit Therapeutics (SMMT) Competitors

$14.25 -0.03 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$14.26 +0.01 (+0.06%)

As of 07:57 PM Eastern

Compare

SMMT vs. MRK, LPA, TEVA, RVMD, and ONC

Should you buy Summit Therapeutics stock or one of its competitors? MarketBeat compares Summit Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Summit Therapeutics include Merck & Co., Inc. (MRK), Logistic Properties of the Americas (LPA), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), and BeOne Medicines (ONC).

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summit Therapeutics (NASDAQ:SMMT) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Summit Therapeutics has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Merck & Co., Inc. has a net margin of 13.59% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 27.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Merck & Co., Inc.	13.59%	27.55%	10.73%

Summit Therapeutics presently has a consensus target price of $27.23, suggesting a potential upside of 91.05%. Merck & Co., Inc. has a consensus target price of $128.18, suggesting a potential upside of 7.07%. Given Summit Therapeutics' higher possible upside, equities analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Merck & Co., Inc.	$65.77B	4.50	$18.25B	$3.55	33.72

In the previous week, Merck & Co., Inc. had 51 more articles in the media than Summit Therapeutics. MarketBeat recorded 53 mentions for Merck & Co., Inc. and 2 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.37 beat Summit Therapeutics' score of 0.84 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Merck & Co., Inc.	46 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Merck & Co., Inc. beats Summit Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summit Therapeutics (NASDAQ:SMMT) and Logistic Properties of the Americas (NYSEAMERICAN:LPA) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Logistic Properties of the Americas has a net margin of 6.31% compared to Summit Therapeutics' net margin of 0.00%. Logistic Properties of the Americas' return on equity of 1.08% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Logistic Properties of the Americas	6.31%	1.08%	0.49%

Summit Therapeutics currently has a consensus price target of $27.23, suggesting a potential upside of 91.05%. Logistic Properties of the Americas has a consensus price target of $7.50, suggesting a potential upside of 102.70%. Given Logistic Properties of the Americas' higher probable upside, analysts clearly believe Logistic Properties of the Americas is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Logistic Properties of the Americas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of Logistic Properties of the Americas shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 32.0% of Logistic Properties of the Americas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Logistic Properties of the Americas	$50.13M	2.33	$10.50M	N/A	N/A

In the previous week, Logistic Properties of the Americas had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for Logistic Properties of the Americas and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat Logistic Properties of the Americas' score of 0.29 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Logistic Properties of the Americas	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Logistic Properties of the Americas has a beta of 5.29, suggesting that its stock price is 429% more volatile than the broader market.

Summary

Logistic Properties of the Americas beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 25.99%. Summit Therapeutics has a consensus price target of $27.23, indicating a potential upside of 91.05%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Summit Therapeutics' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Teva Pharmaceutical Industries had 29 more articles in the media than Summit Therapeutics. MarketBeat recorded 31 mentions for Teva Pharmaceutical Industries and 2 mentions for Summit Therapeutics. Teva Pharmaceutical Industries' average media sentiment score of 0.96 beat Summit Therapeutics' score of 0.84 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	19 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.35B	2.20	$1.41B	$1.33	24.93
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Revolution Medicines' return on equity of -83.22% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Revolution Medicines had 20 more articles in the media than Summit Therapeutics. MarketBeat recorded 22 mentions for Revolution Medicines and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat Revolution Medicines' score of 0.29 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines presently has a consensus target price of $123.72, indicating a potential downside of 27.01%. Summit Therapeutics has a consensus target price of $27.23, indicating a potential upside of 91.05%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Revolution Medicines beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Summit Therapeutics compare to BeOne Medicines?

Summit Therapeutics (NASDAQ:SMMT) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

BeOne Medicines has a net margin of 8.94% compared to Summit Therapeutics' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
BeOne Medicines	8.94%	12.06%	6.69%

Summit Therapeutics currently has a consensus price target of $27.23, indicating a potential upside of 91.05%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 41.24%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, BeOne Medicines had 10 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for BeOne Medicines and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.84 beat BeOne Medicines' score of -0.18 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summit Therapeutics has a beta of -1.32, indicating that its share price is 232% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BeOne Medicines has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
BeOne Medicines	$5.34B	5.67	$286.93M	$4.47	61.77

Summary

BeOne Medicines beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMMT vs. The Competition

Export

Metric	Summit Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.06B	$2.97B	$6.46B	$12.11B
Dividend Yield	N/A	1.78%	2.68%	5.81%
P/E Ratio	-8.91	18.43	24.71	24.00
Price / Sales	N/A	345.21	492.47	90.40
Price / Cash	N/A	55.91	27.92	37.84
Price / Book	16.76	4.11	10.82	6.53
Net Income	-$1.08B	$64.45M	$3.56B	$336.99M
7 Day Performance	2.67%	2.24%	1.67%	-0.22%
1 Month Performance	-14.26%	1.04%	0.43%	0.77%
1 Year Performance	-30.11%	30.05%	32.84%	31.57%

Summit Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMMT Summit Therapeutics	3.8349 of 5 stars	$14.25 -0.2%	$27.23 +91.1%	-30.5%	$11.06B	N/A	N/A	110	Gap Down
MRK Merck & Co., Inc.	4.4648 of 5 stars	$114.04 +0.1%	$128.18 +12.4%	+45.7%	$281.24B	$65.01B	32.12	75,000	Trending News High Trading Volume
LPA Logistic Properties of the Americas	4.2132 of 5 stars	$3.57 flat	$7.50 +110.1%	-47.9%	$112.88M	$50.13M	35.70	30	Gap Up High Trading Volume
TEVA Teva Pharmaceutical Industries	4.5763 of 5 stars	$31.50 +0.1%	$41.78 +32.6%	+90.0%	$36.20B	$17.26B	23.68	33,950	Positive News Options Volume
RVMD Revolution Medicines	1.6602 of 5 stars	$162.99 flat	$123.72 -24.1%	+318.1%	$34.65B	$11.58M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMMT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, TEVA, RVMD, and ONC

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Summary

How does Summit Therapeutics compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, TEVA, RVMD, and ONC

How does Summit Therapeutics compare to Merck & Co., Inc.?

Which has more volatility and risk, SMMT or MRK?

Do institutionals and insiders hold more shares of SMMT or MRK?

Is SMMT or MRK more profitable?

Do analysts recommend SMMT or MRK?

Which has preferable valuation and earnings, SMMT or MRK?

Does the media refer more to SMMT or MRK?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Is SMMT or LPA more profitable?

Do analysts recommend SMMT or LPA?

Do institutionals & insiders hold more shares of SMMT or LPA?

Which has stronger earnings & valuation, SMMT or LPA?

Does the media refer more to SMMT or LPA?

Which has more risk & volatility, SMMT or LPA?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Do analysts rate TEVA or SMMT?

Which has more risk & volatility, TEVA or SMMT?

Is TEVA or SMMT more profitable?

Does the media prefer TEVA or SMMT?

Which has preferable earnings and valuation, TEVA or SMMT?

Do institutionals and insiders have more ownership in TEVA or SMMT?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Is RVMD or SMMT more profitable?

Does the media refer more to RVMD or SMMT?

Do analysts prefer RVMD or SMMT?

Which has more risk & volatility, RVMD or SMMT?

Which has better earnings & valuation, RVMD or SMMT?

Do institutionals & insiders believe in RVMD or SMMT?

Summary

How does Summit Therapeutics compare to BeOne Medicines?

Is SMMT or ONC more profitable?

Do analysts prefer SMMT or ONC?

Does the media refer more to SMMT or ONC?

Which has more volatility & risk, SMMT or ONC?

Do institutionals and insiders believe in SMMT or ONC?

Which has preferable valuation & earnings, SMMT or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools